NCT05858619View on ClinicalTrials.gov

Molecular Signatures of Cutaneous Dupilumab Response

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

dupilumab 600 mg injection initially and then 300 mg every other week

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER